No Data
OCUMENSION-B (01477.HK) spent 0.1186 million Hong Kong dollars to repurchase 0.027 million shares on December 24.
Gelonghui reported on December 24 that OCUMENSION-B (01477.HK) announced that on December 24, it spent 0.1186 million HKD to repurchase 0.027 million shares, with a repurchase price of 4.37-4.41 HKD per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
On December 19, OCUMENSION-B (01477.HK) spent 1.41 million Hong Kong dollars to repurchase 0.31 million shares.
Gelonghui reported on December 19 that OCUMENSION-B (01477.HK) announced it spent 1.41 million Hong Kong dollars to repurchase 0.31 million shares on December 19.
On December 18, OCUMENSION-B (01477) spent 0.0446 million Hong Kong dollars to repurchase 9,500 shares.
OCUMENSION-B (01477) announced that on December 18, 2024, the company will invest 4.4...
On December 17, OCUMENSION-B (01477) spent approximately 0.0283 million HKD to repurchase 6,000 shares.
OCUMENSION-B (01477) announced that on December 17, 2024, it spent approximately 0.0283 million Hong Kong dollars to repurchase...
On December 16, OCUMENSION-B (01477) spent approximately 0.0571 million HKD to repurchase 0.012 million shares.
OCUMENSION-B (01477) announced that on December 16, 2024, it spent approximately 0.0571 million HKD to repurchase...
Companies Like Ocumension Therapeutics (HKG:1477) Are In A Position To Invest In Growth
